Comparing standard treatment with and without Ribavirin for dengue fever

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of adding Ribavirin to standard treatment in preventing significant bleeding in patients with dengue fever. It is a double-blind, randomized controlled trial that aims to determine if Ribavirin improves clinical outcomes compared to standard treatment alone. Conducted in multiple hospitals in Khyber Pakhtunkhwa, the trial employs rigorous methodologies including block randomization and double-blinding. Key outcomes measured include changes in bleeding severity, platelet counts, and length of hospital stay, with the goal of enhancing dengue management protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female patients aged 18 years and above.
* Hospitalized patients diagnosed with dengue fever, confirmed via:
* Positive Dengue NS1 antigen test
* Dengue IgM antibodies
* Dengue RNA PCR.
* Patients presenting with various severities of illness, as classified by the WHO dengue severity classification.

Exclusion Criteria:

* Patients taking antiplatelet or anticoagulant medications.
* Patients with known bleeding disorders (e.g., hemophilia, von Willebrand disease, end-stage renal disease, or liver cirrhosis).
* Patients with HIV undergoing antiviral therapy.
* Pregnant women.
* Patients with hypersensitivity to Ribavirin.
* Patients with WHO Grade 1 bleeding (few petechiae without clinical significance).

Where it's running

• Lady Reading Hospital
  Peshawar, Khyber Pakhtunkhwa, Pakistan Recruiting
• Gandhara Medical Hospital
  Peshawar, Khyber Pakhtunkhwa, Pakistan Recruiting
• Medical Complex Swabi
  Swābi, Khyber Pakhtunkhwa, Pakistan Recruiting
• Kohat Institute of Medical Science
  Kohat, Kpk, Pakistan Recruiting

Study contacts

• Principal investigator: Said Amin, MBBS,FCPS — Department of Medicine Hayatabad Medical Complex Peshawar
• Study coordinator: Said Amin, MBBS, FCPS
• Email: saidamin@live.com
• Phone: +92-333-9115488

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut leakage in dengue: is the intestinal barrier affected during infection?

  Researchers are studying whether dengue infection disrupts the gut barrier and if that contributes to severe disease in adults with dengue who are in hospital.

  Recruiting University of Oxford · Chittagong, Chattogram Division · NCT07602920

• Registry of dengue infection in people with congenital bleeding disorders

  This registry will collect information to see how dengue affects people with congenital bleeding disorders, such as hemophilia and von Willebrand disease, and what treatments and outcomes occur.

  Recruiting Mahidol University · Bangkok · NCT07409857

• Risk factors for hospitalization and transfusion criteria in dengue patients

  This project will try to find which clinical signs and lab results predict whether people aged 5 and up with confirmed dengue will need hospitalization or a blood transfusion.

  Recruiting Clinica Mexico · Piedras Negras, Coahuila · NCT07007585

• Resomelagon in Dengue Infection: Safety and Function in Adults

  This study tests whether Resomelagon can be safely given to adults with dengue fever to see if it shortens illness compared with placebo.

  Recruiting Phase 2 Federal University of Minas Gerais · Belo Horizonte, Minas Gerais and 1 other locations · NCT06917001

• Effectiveness of Dengue Vaccine in Children and Adolescents

  This study is testing how well a new dengue vaccine works to keep children and teens in Southeast Asia out of the hospital due to dengue fever.

  Recruiting at 3 sites Takeda · Banjarmasin, South Kalimantan and 6 other locations · NCT06843226

• Innovative strategies to understand and combat severe dengue

  This study is trying to find out what makes dengue infections more severe by looking at blood samples from patients in areas where dengue is common, to help improve treatment and prevention.

  Recruiting at 2 sites Karolinska Institutet · Guatemala City and 1 other locations · NCT06751836

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.